Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

Bicara Therapeutics Inc. ( (BCAX) ) has released its Q3 earnings. Here is a breakdown of the information Bicara Therapeutics Inc. presented to ...

Robert W. Baird has recently initiated Lexeo Therapeutics Inc (LXEO) stock to Outperform rating, as announced on June 13, 2024, according to Finviz. Earlier, on June 6, 2024, H.C. Wainwright had ...

CLEVELAND (AP) — CLEVELAND (AP) — Abeona Therapeutics Inc. (ABEO) on Thursday reported a loss of $20.3 million in its third quarter. On a per-share basis, the Cleveland-based company said it had a ...

Begin your TipRanks Premium journey today. PTC Therapeutics (PTCT) Company Description: PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of ...

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago. These ...

Call Scheduled for Thursday, November 14, 2024 at 5:00 pm ETLITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical ...

MiNK ended the quarter with a cash balance of $6.3 million reflecting cash used in operations for the three and nine months ended September 2024 of $3 million and $7.8 million, respectively, reduced ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, ...

The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon ...